Summit Therapeutics Inc. Logo

Summit Therapeutics Inc.

Advancing a Phase 3 bispecific antibody for lung cancer and other solid tumors.

SMMT | US

Overview

Corporate Details

ISIN(s):
US86627T1088
LEI:
Country:
United States of America
Address:
601 BRICKELL KEY DRIVE, 33131 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies in oncology. The company aims to address serious unmet medical needs and improve the quality and potential duration of life for patients with difficult cancer diagnoses. Its lead asset is ivonescimab (SMT112), a potential first-in-class, investigational bispecific antibody that combines the effects of immunotherapy (PD-1 blockade) and anti-angiogenesis (VEGF blockade) into a single molecule. Summit is advancing ivonescimab through multiple Phase 3 clinical trials, with an initial focus on non-small cell lung cancer (NSCLC) and plans for expansion into other solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Summit Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Summit Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Summit Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.
United States of America CUPR
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curanex Pharmaceuticals Inc Logo
Developing botanical drugs for inflammatory diseases, diabetes, and COVID-19.
United States of America CURX
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC
CureVac N.V. Logo
Pioneering mRNA technology for prophylactic vaccines and novel cancer immunotherapies.
United States of America CVAC
CURIS INC Logo
Biotech developing innovative cancer therapeutics for hematologic malignancies.
United States of America CRIS
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
CYBIN INC. Logo
A clinical-stage firm engineering novel psychedelic drugs for depression and anxiety.
United States of America CYBN
Cyclerion Therapeutics, Inc. Logo
Developing personalized therapy for TRD with a biofeedback device and anesthetics.
United States of America CYCN
Cyfuse Biomedical K.K. Logo Japan 4892

Talk to a Data Expert

Have a question? We'll get back to you promptly.